Evidence map›Paper›PMID 39165594›Full record

ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2024

Value of [

Paulina Cegla, Frank Hofheinz, Rafał Czepczyński, Kamila Witkowska, Jörg van den Hoff, Maciej Trojanowski, Agnieszka Bos-Liedke, Witold Cholewinski

Abstract read
In one paragraph

Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Paulina CeglaDepartment of Nuclear Medicine, Greater Poland Cancer Centre, Poznan, Poland.
Frank HofheinzHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Rafał CzepczyńskiDepartment of Nuclear Medicine, Affidea, Poznan, Poland.
Kamila WitkowskaDepartment of Nuclear Medicine, Affidea, Poznan, Poland.
Jörg van den HoffHelmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Maciej TrojanowskiGreater Poland Cancer Registry, Greater Poland Cancer Centre, Poznan, Poland.
Agnieszka Bos-LiedkeDepartment of Biomedical Physics, Adam Mickiewicz University, Poznan, Poland.
Witold CholewinskiDepartment of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The aim of this retrospective study was to assess the value of Materials and methods: 59 consecutive patients (35 M, 24 F) with NSCLC who underwent pretreatment [ Results: In the whole analysed group 44 patients underwent curative treatment, while 15, because of the severity of the disease, were classified for palliative treatment. Univariate Cox analysis of clinical and metric PET parameters revealed that MTV was a significant prognostic factor for OS (p = 0.024), while TLG and curative treatment showed a trend for significance (p < 0.1). In multivariate Cox regression (MTV and curative treatment) MTV remained a significant factor (p = 0.047). Conclusions: Metabolic tumor volume of the primary tumor was the only independent prognostic factor for cN1-cN3 NSCLC patients.

Indexed as

NSCLCoverall survivalpositron emission tomography/computed tomography

Identifiers

PMID39165594
PMCPMC11333082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.